Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls
- 6 May 2011
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (9), 1702-1714
- https://doi.org/10.1007/s00259-011-1821-1
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Cognition, glucose metabolism and amyloid burden in Alzheimer's diseaseNeurobiology of Aging, 2012
- Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer’sProceedings of the National Academy of Sciences, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Conversion of amyloid positive and negative MCI to AD over 3 yearsNeurology, 2009
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984